Banque Transatlantique SA Purchases 720,499 Shares of EDAP TMS S.A. $EDAP

Key Points

• Banque Transatlantique SA significantly increased its holdings in Edap Tms by 7,063.7% in the first quarter, acquiring an additional 720,499 shares and owning about 1.97% of the company valued at $1,324,000.
• Analysts have shifted their outlook on Edap Tms, with Piper Sandler downgrading the stock from an "overweight" to a "neutral" rating, reflecting a consensus rating of "Hold" and an average price target of $8.50.
• Edap Tms currently has a market cap of $103.20 million, with a price range over the last year between $1.21 and $3.77, indicating volatility in its stock price.

Banque Transatlantique SA lifted its holdings in shares of EDAP TMS S.A. (NASDAQ:EDAP - Free Report) by 7,063.7% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 730,699 shares of the medical equipment provider's stock after buying an additional 720,499 shares during the quarter. Banque Transatlantique SA owned about 1.97% of EDAP TMS worth $1,324,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of EDAP. Scoggin Management LP acquired a new stake in shares of EDAP TMS during the 1st quarter worth approximately $686,000. Jane Street Group LLC grew its holdings in EDAP TMS by 174.7% during the fourth quarter. Jane Street Group LLC now owns 31,361 shares of the medical equipment provider's stock valued at $69,000 after purchasing an additional 73,361 shares during the period. Schonfeld Strategic Advisors LLC grew its holdings in EDAP TMS by 48.5% during the fourth quarter. Schonfeld Strategic Advisors LLC now owns 160,800 shares of the medical equipment provider's stock valued at $355,000 after purchasing an additional 52,500 shares during the period. Millennium Management LLC grew its holdings in EDAP TMS by 218.5% during the fourth quarter. Millennium Management LLC now owns 48,915 shares of the medical equipment provider's stock valued at $108,000 after purchasing an additional 33,558 shares during the period. Finally, BNP Paribas Financial Markets grew its holdings in EDAP TMS by 111.5% during the fourth quarter. BNP Paribas Financial Markets now owns 48,650 shares of the medical equipment provider's stock valued at $108,000 after purchasing an additional 25,650 shares during the period. Institutional investors and hedge funds own 62.74% of the company's stock.

EDAP TMS Price Performance

Shares of EDAP stock remained flat at $2.52 during trading on Friday. 134,627 shares of the stock were exchanged, compared to its average volume of 171,560. The firm's 50 day moving average is $1.58 and its two-hundred day moving average is $1.83. The company has a current ratio of 1.51, a quick ratio of 1.05 and a debt-to-equity ratio of 0.04. The stock has a market capitalization of $94.22 million, a P/E ratio of -4.13 and a beta of -0.21. EDAP TMS S.A. has a twelve month low of $1.21 and a twelve month high of $3.29.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on EDAP shares. Wall Street Zen started coverage on shares of EDAP TMS in a report on Thursday, May 15th. They set a "hold" rating for the company. Piper Sandler cut shares of EDAP TMS from an "overweight" rating to a "neutral" rating in a report on Thursday, May 15th. One analyst has rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, EDAP TMS presently has a consensus rating of "Hold" and a consensus price target of $8.50.

EDAP TMS Company Profile

EDAP TMS SA is a holding company, which, through its subsidiary, engages in the development, production, and marketing of minimally invasive medical devices for urological diseases. It operates through the High Intensity Focused Ultrasound (HIFU) and Urology Devices and Services (UDS) segments. The HIFU segment develops, manufactures, and markets devices for the minimally invasive ablation of certain types of localized tumors using HIFU technology.